921 related articles for article (PubMed ID: 32121574)
1. Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review.
Kamata M; Tada Y
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32121574
[TBL] [Abstract][Full Text] [Related]
2. New biologics for psoriasis and psoriatic arthritis.
Rozenblit M; Lebwohl M
Dermatol Ther; 2009; 22(1):56-60. PubMed ID: 19222517
[TBL] [Abstract][Full Text] [Related]
3. Depression and Insomnia in Patients With Psoriasis and Psoriatic Arthritis Taking Tumor Necrosis Factor Antagonists.
Wu CY; Chang YT; Juan CK; Shen JL; Lin YP; Shieh JJ; Liu HN; Chen YJ
Medicine (Baltimore); 2016 May; 95(22):e3816. PubMed ID: 27258525
[TBL] [Abstract][Full Text] [Related]
4. Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review.
Armstrong AW; Brezinski EA; Follansbee MR; Armstrong EJ
Curr Pharm Des; 2014; 20(4):500-12. PubMed ID: 23565631
[TBL] [Abstract][Full Text] [Related]
5. Current and emerging biologic and small molecule systemic treatment options for psoriasis and psoriatic arthritis.
Lin CP; Merola JF; Wallace EB
Curr Opin Pharmacol; 2022 Dec; 67():102292. PubMed ID: 36228472
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular comorbidities of psoriasis and psoriatic arthritis: a report from the GRAPPA 2012 annual meeting.
Armstrong AW; Gelfand JM; Boehncke WH; Armstrong EJ
J Rheumatol; 2013 Aug; 40(8):1434-7. PubMed ID: 23908540
[TBL] [Abstract][Full Text] [Related]
7. New generation biologics for the treatment of psoriasis and psoriatic arthritis. State of the art and considerations about the risk of infection.
Ceccarelli M; Venanzi Rullo E; Berretta M; Cacopardo B; Pellicanò GF; Nunnari G; Guarneri C
Dermatol Ther; 2021 Jan; 34(1):e14660. PubMed ID: 33301216
[TBL] [Abstract][Full Text] [Related]
8. Infectious, oncologic, and autoimmune comorbidities of psoriasis and psoriatic arthritis: a report from the GRAPPA 2012 annual meeting.
Armstrong AW; Coates LC; Espinoza LR; Ogdie AR; Rich P; Soriano ER
J Rheumatol; 2013 Aug; 40(8):1438-41. PubMed ID: 23908541
[TBL] [Abstract][Full Text] [Related]
9. Estimating Cardiovascular Impacts of Drugs for Psoriatic Disease: A Long Way to Go.
Siebert S; Sattar N
J Invest Dermatol; 2021 Oct; 141(10):2322-2325. PubMed ID: 34560915
[TBL] [Abstract][Full Text] [Related]
10. Biologics and Psoriasis: The Beat Goes On.
Kim HJ; Lebwohl MG
Dermatol Clin; 2019 Jan; 37(1):29-36. PubMed ID: 30466686
[TBL] [Abstract][Full Text] [Related]
11. Epidemiological survey of patients with psoriatic arthritis in the Japanese Society for Psoriasis Research from 2017 to 2020.
Kamiya K; Ohtsuki M
J Dermatol; 2023 Jan; 50(1):12-25. PubMed ID: 36261862
[TBL] [Abstract][Full Text] [Related]
12. Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University Psoriasis Registry.
Bayaraa B; Imafuku S
J Dermatol; 2019 May; 46(5):389-398. PubMed ID: 30861182
[TBL] [Abstract][Full Text] [Related]
13. Impact of psoriatic arthritis and comorbidities on ustekinumab outcomes in psoriasis: a retrospective, observational BADBIR cohort study.
Tillett W; Ogdie A; Passey A; Gorecki P
RMD Open; 2023 Jan; 9(1):. PubMed ID: 36650006
[TBL] [Abstract][Full Text] [Related]
14. An evidence-based review of the mechanism of action, efficacy, and safety of biologic therapies in the treatment of psoriasis and psoriatic arthritis.
Brezinski EA; Armstrong AW
Curr Med Chem; 2015; 22(16):1930-42. PubMed ID: 25921645
[TBL] [Abstract][Full Text] [Related]
15. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey.
van de Kerkhof PC; Reich K; Kavanaugh A; Bachelez H; Barker J; Girolomoni G; Langley RG; Paul CF; Puig L; Lebwohl MG
J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):2002-10. PubMed ID: 25885420
[TBL] [Abstract][Full Text] [Related]
16. Secukinumab for treating plaque psoriasis.
Rothstein B; Gottlieb A
Expert Opin Biol Ther; 2016; 16(1):119-28. PubMed ID: 26577956
[TBL] [Abstract][Full Text] [Related]
17. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
Menter A; Gottlieb A; Feldman SR; Van Voorhees AS; Leonardi CL; Gordon KB; Lebwohl M; Koo JY; Elmets CA; Korman NJ; Beutner KR; Bhushan R
J Am Acad Dermatol; 2008 May; 58(5):826-50. PubMed ID: 18423260
[TBL] [Abstract][Full Text] [Related]
18. Bimekizumab for the treatment of psoriatic disease.
Natsis NE; Gottlieb AB
Expert Opin Biol Ther; 2018 Dec; 18(12):1193-1197. PubMed ID: 30332893
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S
J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
[TBL] [Abstract][Full Text] [Related]
20. [The role of biologics into the management of psoriasis: a consensus paper by the Psoriasis Study Group, Arbeitsgemeinschaft Dermatologische Forschung].
Wolf-Henning B; Friedrich M; Mrowietz U; Reich K; Rosenbach T; Sticherling M; Thaçi D;
J Dtsch Dermatol Ges; 2003 Aug; 1(8):620-8. PubMed ID: 16296152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
